A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease

Trial Profile

A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs CT 1812 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms SPARC
  • Sponsors Cognition Therapeutics
  • Most Recent Events

    • 23 Jul 2018 According to a Cognition Therapeutics media release, data from this trial was presented at the Alzheimer's Association International Conference (AAIC).
    • 18 Jun 2018 According to a Cognition Therapeutics media release,,Status changed from recruiting to active, no longer recruiting.
    • 18 Jun 2018 According to a Cognition Therapeutics media release, patient dosing has begun in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top